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Abstract
Objectives—To estimate the long-term risk of sling revision/removal after an initial sling and to
assess indications (mesh erosion and urinary retention) and predictors of sling revision/removal.
Study Design—Using a population-based cohort of commercially insured individuals, we
identified women ≥ 18 who underwent a sling (CPT 57288) between 2001–2010 and any
subsequent sling revision/removal (CPT 57287). We estimated the cumulative risk of revision/
removal annually and evaluated predictors of sling revision/removal using Kaplan-Meier survival
curves and Cox proportional hazards models, respectively.
Results—We identified 188,454 eligible women who underwent an index sling. The 9-year
cumulative risk of sling revision/removal was 3.7% (95%CI 3.5, 3.9). At one year, this risk was
already 2.2% and then increased to 3.2% at four years before plateauing. Regarding the indication
for the sling revision/removal, a greater proportion was due to mesh erosion compared to urinary
retention, with a 9-year risk of 2.5% (95%CI 2.3, 2.6) for mesh erosion versus 1.3% (95%CI 1.2,
1.4) for urinary retention. Age had an effect on revision/removal rates for both mesh erosion and
urinary retention, with the higher risks among those aged 18–29. The risk of revision/removal for
mesh erosion and urinary retention was also elevated among women who had a concomitant
anterior or apical prolapse procedure.
Conclusions—In this population-based analysis, the 9-year risk of sling revision/removal was
relatively low at 3.7%, with 60% of revisions/removals due to mesh erosion.
© 2012 Mosby, Inc. All rights reserved.
Corresponding Author: Jennifer M. Wu, MD, MPH, Duke University Medical Center, Box 3192, 5324 McFarland Avenue, Suite 310,
Durham, North Carolina 27707, Work: (919) 401-1006, Home: (919) 452-4577, Fax: (919) 401-1034, jennifer.wu@duke.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Disclosure: None of the authors have any relevant conflicts of interest
The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for
Healthcare Research and Quality.




Am J Obstet Gynecol. Author manuscript; available in PMC 2014 January 01.
Published in final edited form as:











mesh erosion; sling; sling removal; sling revision; urinary retention
INTRODUCTION
Slings represent the most common surgery for stress urinary incontinence (SUI) and are now
considered the gold standard procedure.1, 2 Historically, “slings” referred to bladder neck
slings,3 which remain an effective surgery for SUI.4 However, midurethral slings now
dominate the surgical management of stress incontinence. The uptake of the midurethral
synthetic mesh sling has increased dramatically since the introduction of the Tension-free
Vaginal Tape® in the United States in 1998.5 Over the last decade, the retropubic
midurethral sling has been modified, and the category of midurethral slings now includes
transobturator slings as well as “mini-slings.”
The adoption of the midurethral sling was supported by level I evidence, which
demonstrated similar five-year effectiveness of retropubic midurethral slings and Burch
colposuspensions,6 the prior gold standard SUI procedure. Furthermore, randomized trials
have reported equivalence between retropubic and transobturator slings at one year.7, 8
Although high quality data from randomized trials exist regarding long-term effectiveness of
midurethral slings, long-term population-based data are limited regarding the need for repeat
surgery to manage complications such as mesh erosion or urinary retention. The best
available data on complications suggest that the risk of sling revision/removal for either
mesh erosion or retention is fairly low, ranging from approximately 1 – 3%8, 9 and 0.6 –
1.2%,8, 9 respectively. To date, the largest observational cohort reported on fewer than 4,000
sling procedures followed for a maximum of 21 months.9 Thus, long-term follow-up of
patients treated in ‘real-world’ clinical settings are needed to further characterize the rates of
repeat surgery to manage complications such as mesh erosion or urinary retention.
The recent FDA notification regarding vaginal mesh for prolapse10 has simultaneously
increased the attention directed at midurethral slings, as these procedures involve synthetic
mesh placed vaginally. While the FDA notification specifically addresses vaginal mesh
prolapse procedures, an update on January 4, 2012 stated that “the FDA continues to
evaluate the effects of using surgical mesh for treatment of urine leakage during moments of
physical activity (stress urinary incontinence) and will provide updates on this webpage at a
later date.” Thus, the FDA verdict regarding mesh slings for SUI is pending.
For relatively new procedures, it is critical to conduct long-term outcome assessments. For
the midurethral sling, an important outcome to assess is the risk of a sling revision or
removal to manage complications such as a mesh erosion or urinary retention. Given the
FDA emphasis on evaluating medical devices involving vaginal mesh and the limited, long-
term, population-based data regarding slings, the objective of this study was to estimate the
long-term risk of sling revision/removal after an initial sling in a large, population-based
cohort. Our secondary objective was to assess the indication for sling revision/removal
(mesh erosion and urinary retention) as well as predictors of revision/removal.
MATERIALS AND METHODS
Data Source
We utilized the Thomson Reuters MarketScan® Commercial Claims and Encounters
(CC&E) and Medicare Supplemental Coordination of Benefits database from 2001–2010
(copyright © 2011 Thomson Healthcare Incorporated Inc).11 This database contains de-
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identified, individual-level healthcare utilization and enrollment data for inpatient,
outpatient, and pharmacy visits from approximately 100 employer-based plans in the United
States. These de-identified data represent the medical experience of privately-insured
employees, retirees, covered spouses and dependents. This database has been rigorously
evaluated and is valid and reliable.12 Individuals can be followed longitudinally using
encrypted unique identification numbers, and enrollment data allowed us to determine which
individuals have insurance coverage at any point in time. This database provided
information on 44.8 million women aged 18 years and older between the years 2001 to
2010. This study was determined to be exempt from further review by the Institutional
Review Board at the University of North Carolina at Chapel Hill.
Inclusion Criteria and Index Sling
The population of interest included all women aged 18 years and older from 2001 to 2010.
The first, or index, sling was identified for each woman, based on current procedural
terminology (CPT) code 57288. We included women with at least 90 days of continuous
enrollment prior to the procedure. Those with a diagnosis of a urethral diverticulum
(International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM)
code 619.0) or any urinary-genital tract fistula (codes 599.1 and 599.2) in the 90 days prior
to the index surgery were excluded. If an additional SUI procedure (i.e. a different type of
SUI surgery such as a Burch colposuspension) was coded on the same date as the sling,
these individuals were excluded. The location for the procedure was also assessed, whether
inpatient or outpatient. If both an inpatient and outpatient procedure claim occurred on the
same service date, we preferentially included the inpatient procedure.
Sling Revision/Removal
After the index sling, the first subsequent sling revision/removal was identified using CPT
code 57287. If another SUI surgery was performed after the index sling (i.e. another sling,
Burch colposuspension, bulking agent, etc…), the outcomes of these individuals were
censored at that surgery date, as we were unable to determine whether any subsequent
revision/removal was secondary to the index sling or the repeat SUI procedure. Otherwise,
individuals were censored at the earliest disenrollment or on December 31, 2010.
In addition to identifying sling revision/removals, we assessed the indication for this
procedure based on ICD-9-CM codes for mesh erosion (996.30, 996.39, 996.59, 996.60,
996.65, 996.69, 996.70, 996.76, 996.79, 939.0, 939.2, and 939.9) and urinary retention
(596.0, 598.1, 598.2, 598.8, 598.9, 599.6, 599.69, 788.2, 788.21, 788.29, 788.61, 788.62,
and 788.65). We did not utilize 629.3 (Complication of implanted vaginal mesh and other
prosthetic materials), 629.31 (erosion of implanted vaginal mesh) or 629.32 (exposure of
implanted vaginal mesh), as these ICD-9 codes were not released until 2011,13 and, thus,
were not applicable during our study period. It is important to note that the diagnoses of
mesh erosion and/or urinary retention were not mutually exclusive; thus, both mesh erosion
and urinary retention could be associated with a single sling revision/removal procedure. For
the indication-specific outcome definitions, individuals were censored if they had a revision/
removal for another indication.
Statistical Analysis
Descriptive statistics were used to characterize the population of women who underwent an
index sling procedure. Kaplan-Meier survival curves were used to estimate the cumulative
incidence (with 95% confidence intervals) of sling revision/removal at 3 months, 6 months,
and annually through 9 years of follow-up. We also estimated the cumulative incidence of
sling revision/removal for mesh erosion and urinary retention separately. In order to explore
the potential for differences in the risk of these outcomes due to the year when the index
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sling was placed, we also compared the cumulative risk at one year after the index sling,
stratified by calendar year in which the index sling was performed.
We used Cox proportional hazards models to estimate the adjusted hazard ratio (adjHR) of
the following: 1) sling revision/removal separately by decade of age (18–29, 30–39, 40–49,
50–59, 60–69) at the time of the index surgery compared to those 70 years of age and older;
2) inpatient versus outpatient procedures; 3) concomitant hysterectomy; and 4) concomitant
prolapse procedures. In order to further examine the possibility of different effects of these
risk factors on revision/removal for mesh erosion and urinary retention, we also estimated
adjHRs separately for each of these outcomes. We estimated 95% confidence intervals on all
effect estimates. Statistical analyses were performed using SAS, v9.2 (SAS Institute, Cary,
NC).
RESULTS
Of the 44.8 million women aged 18 years or older from 2001–2010, there were 188,454
index sling procedures. The median age of women undergoing surgery was 53 years
(interquartile range 45, 61), and approximately 60% of these procedures were performed in
women aged 40–59 years of age (Table 1). Table 1 also depicts the year in which the index
sling was performed and illustrates that a higher proportion of surgeries were done in the
latter years reflecting an increase in the database’s enrolled population. Because the majority
of procedures were performed in the latter portion of the decade, there are relatively more
procedures with shorter time intervals of follow-up (Table 1). Nonetheless, we have four or
more years of follow-up on 25,219 individuals, and more than eight years on 1,864
individuals. A majority (67%) of the procedures was performed on an outpatient basis, and
the South had the largest proportion of sling procedures (49%). Concomitant hysterectomy
and concurrent prolapse procedures were also common (Table 1).
The cumulative incidence of sling revision/removal for any indication was 3.7% (95%CI
3.5, 3.9) at nine years of follow-up (Table 2). At one year of follow-up, this risk was 2.2%
and then increased to 3.2% at four years before plateauing. Thus, a majority of sling
revision/removals occurred within the first few years after the index surgery. Regarding the
indication for the sling revision/removal, a greater proportion was due to mesh erosion
compared to urinary retention, with a nine-year risk of 2.5% (95%CI 2.3, 2.6) for mesh
erosion versus 1.3% (95%CI 1.2, 1.4) for urinary retention. Focusing on mesh erosion, the
risk of revision/removal increased from 1.3% at one year to 2.1% at four years before
leveling off. For urinary retention, the risk was 0.9% at one year and then remained fairly
stable afterwards.
In order to further evaluate possible changes over time in the risk of revision/removal for
mesh erosion and urinary retention, we estimated the one-year risk for sling revision/
removal by indication for each calendar year (Figure 1). This analysis was prompted
because the type of midurethral slings performed (i.e. retropubic midurethral slings versus
transobturator slings versus “mini-slings”) may have changed during the study period. While
the one-year cumulative risk of sling revision/removal for any indication remained fairly
stable over the study period, there was an increase in the one-year risk of revision/removal
for mesh erosion and a decrease in the risk of surgery for retention over the study period
(Figure 1).
We also evaluated predictors of sling revision/removal based on indication using Cox
proportional hazards models. For revision/removal due to mesh erosion, all women aged 18–
69 were at higher risk compared to those age 70 years and older, with the highest risk among
those 18–39 (Table 3). The risk of revision/removal for mesh erosion was also elevated
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among women who had a concomitant anterior (HR 1.18, 95%CI 1.08, 1.29) or apical (HR
1.24, 95%CI 1.10, 1.41) prolapse procedure, but not among those who had a posterior
prolapse procedure (HR 1.06, 95%CI 0.91, 1.24). Women who had a concurrent
hysterectomy had a lower risk of revision/removal for mesh erosion (HR 0.81, 95%CI 0.73,
0.90).
For sling revision/removal due to urinary retention, women aged 18–29 (HR 1.91, 95%CI
1.22, 2.99) had a significantly higher risk than women aged 70 and older. Inpatient
procedures were also associated with a higher risk of sling revision/removal for retention
compared to outpatient procedures (HR 1.18, 95%CI 1.06, 1.32). Women who had a
concomitant anterior (HR 1.22, 95%CI 1.09, 1.36) or apical (HR 1.43, 95%CI 1.25, 1.64)
prolapse procedure were also at higher risk of subsequent revision/removal for retention
compared to those who did not. Concomitant posterior prolapse procedures and
hysterectomy were not associated with any change in the risk of revision/removal for urinary
retention.
COMMENT
In this large, population-based cohort of 188,454 adult women who underwent an index
sling, the risk of sling revision/removal was relatively low at 3.7% at nine years of follow-
up. The majority of revisions/removals occurred within four years after the index surgery.
Mesh erosion, rather than urinary retention, was the indication for a majority of these
procedures. We also found that risk factors differed for the two primary indications for
revision/removal with a stronger effect of age on mesh erosion.
Our findings regarding the risk of sling revision/removal are consistent with the existing
literature. In the landmark trial of Tension-free Vaginal Tape (TVT) versus Burch
colposuspension, Ward et al. reported that 1/170 (0.6%) TVTs had obstructed voiding
requiring sling revision and 5/170 (2.9%) had erosion/extrusion.6 Other randomized trials of
retropubic versus transobturator slings revealed a 2.7% rate of voiding dysfunction requiring
surgery,7 and rates of erosions and/or exposures ranged from 1.8 – 3.5%, although not all of
these required surgery.7, 8 Prior to our study, the largest population-based study evaluated
3,747 slings over a 21-month time period and found that the rate of sling loosening or
transection was 1.2% for retropubic procedures, 1.9% for transobturator slings and 1.3% for
single-incision surgeries.9 The risk of surgery for vaginal mesh exposure was 0.9% and
1.0% for retropubic and transobturator procedures, respectively.9 While several systematic
reviews and meta-analyses have been performed regarding midurethral slings,14–18 the
cumulative number of subjects in these studies remains significantly lower than our study
population. We extend the literature in that we evaluated over 188,000 index slings with
annual rates for sling revision/removal based on indication through nine years of follow-up.
Our results suggest that the relatively low rate of sling revision/removal in the short-term
does not increase dramatically over the first nine years after surgery.
Our study revealed interesting and surprising findings regarding predictors for sling
revision/removal. Our results showed a strong effect of age on the risk of sling revision/
removal for mesh erosion, with the highest risk among younger women. This was surprising
given that urogenital atrophy occurs in older populations, leading to poorer tissue quality
with a presumably higher risk for mesh erosion. It is possible that younger women were
more sexually active, and sexual activity could be a risk factor for mesh erosion.
Alternatively, younger women who are more sexually active may have been more likely to
detect mesh erosion and to opt for surgical management. Unfortunately, because slings of all
types were coded using CPT code 57288, we were unable to determine which type of sling
was associated with greater risk of mesh erosion.
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Regarding sling revision/removal for urinary retention, we found that the youngest age
group (women 18–29), were at highest risk for repeat surgery, although the strong gradient
of risk by age was not present. These results were also surprising in that older age groups are
more likely to suffer from impaired detrusor contractility,19 which could lead to a higher
risk of urinary retention after slings. Perhaps younger women were less tolerant of irritative
voiding symptoms or de novo urge incontinence, and therefore had a lower threshold to
undergo surgical management in attempts to remedy these symptoms. Other variables
associated with sling revision/removal for urinary retention and mesh erosion included
concurrent anterior or apical prolapse procedures. It is possible that the changes in pelvic
support and anatomy associated with anterior and apical prolapse exacerbated urinary
retention and compromised healing due to the additional vaginal incisions.
We also found that there were differences in the one-year risk of sling revision/removal
based on the year in which the index sling was performed. The risk of surgery for urinary
retention decreased from 2001 to 2010. We hypothesize that as surgeons became more
familiar with how to perform slings, their technique improved. Also, the more recent
introduction of the transobturator and mini-slings may be associated with a lower risk of
surgery for retention, as these slings are less compressive around the urethra.20 On the other
hand, the risk of sling revision/removal for mesh erosion increased over the study period. It
is possible that transobturator slings and certain mini-slings leave more mesh traversing the
vaginal space which could increase the risk for mesh erosion. In addition, the FDA 2008
notification may have led to a higher risk of sling revision/removal for this indication, as it
heightened awareness of mesh erosion as a possible sling complication among both patients
and providers.21
This study provides comprehensive data on over 188,000 index sling procedures with long-
term follow-up over nine years in a nationally representative, population-based cohort. One
unique aspect of these healthcare claims data was that we can accurately account for
individual contributions to follow-up time with complete capture of subsequent clinical care
as long as an individual continued to have insurance coverage. For example, even if a
subject with a sling complication did not follow-up at the same institution in which the
initial sling was performed, follow-up data regarding sling revision/removal was available.
Another benefit of this database was that we were able to follow patients beyond the age of
65 years when they transitioned into Medicare by virtue of the Medicare supplemental data.
This study was limited by the fact that the database only included privately-insured
individuals, and thus, the results may not be generalizable to uninsured or underinsured
individuals. Furthermore, detailed sociodemographic and clinical data such as race, physical
examination findings, such as body mass index, and severity of urinary incontinence were
not available. We were also limited by the specificity of CPT codes in the database.
Currently, there is one encompassing CPT code for all sling procedures, code 57288, which
includes traditional bladder neck, retropubic midurethral slings, transobturator slings, and
mini-slings. The proposed FDA rule that would require unique device identifiers (UDIs) will
make it possible to distinguish specific types of slings, but it will be many years before long-
term outcome data will be available for surgeries in which the UDI has been recorded.22
Lastly, we acknowledge that our data does not represent the overall risk of mesh erosion
after a sling, as some erosions may have been managed conservatively in the office and
some erosions managed surgically may have been coded by a different CPT (i.e. 57295
revise vaginal graft via vaginal approach) and not CPT 57287, which indicates a sling
revision/removal.
In conclusion, after an index sling procedure, the risk of sling revision/removal for either
mesh erosion or urinary retention is < 4% over nine years of follow-up. The majority of
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these sling revisions/removals were due to mesh erosion rather than urinary retention. Age,
slings performed with concomitant prolapse surgery, and the calendar year of the index sling
were associated with the risk of sling revision/removal. Although the FDA evaluation for
slings is still pending,10 these long-term results in a large, population-based cohort are
reassuring. However, future studies should aim to study specific sling types in a large cohort
of women with long-term follow-up.
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Cumulative one-year risk of sling revision for any indication, retention or mesh erosion,
stratified by year of index sling
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Table 1
Characteristics of Women who Underwent an Index Sling
N=188,454 %
Age at Index Sling
     Median (IQR) 53 (45, 61) --
     Mean (SD) 53.7 (11.9) --
     18–29 years 1,314 0.7
     30–39 years 18,429 9.8
     40–49 years 55,248 29.3
     50–59 years 57,208 30.4
     60–69 years 35,150 18.6
     70–79 years 16,183 8.6
     80+ years 4,942 2.6
Year when Index Surgery Performed
     2001 2,322 1.2
     2002 5,026 2.7
     2003 8,835 4.7
     2004 13,350 7.1
     2005 17,445 9.3
     2006 20,437 10.8
     2007 23.066 12.2
     2008 30,155 16.0
     2009 33,654 17.9
     2010 34,164 18.1
Time Intervals of Follow-up
     0 to <2 years 122,213 64.9
     2 to < 4 years 41,022 21.8
     4 to < 6 years 16,827 8.9
     6 to < 8 years 6,528 3.5
     8+ years 1,864 1.0
Outpatient Index Slings 126,443 67.1
Region
     Northeast 13,724 7.3
     Midwest 52,035 27.6
     South 92,145 48.9
     West 29,624 15.7
     Unknown 924 0.5
Concomitant Surgery
     Hysterectomy 47,065 25.0
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N=188,454 %
     Anterior prolapse procedures 62,469 33.2
     Apical prolapse procedures 22,743 12.1
     Posterior prolapse procedures 13,198 7.0
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Table 2












0.25 0.6 (0.5, 0.6) 0.5 (0.5, 0.5) 1.0 (1.0, 1.1)
0.5 0.8 (0.7, 0.8) 0.9 (0.8, 0.9) 1.6 (1.5, 1.6)
1 0.9 (0.9, 1.0) 1.3 (1.2, 1.3) 2.2 (2.1, 2.2)
2 1.1 (1.0, 1.1) 1.6 (1.6, 1.7) 2.6 (2.5, 2.7)
3 1.2 (1.1, 1.2) 1.9 (1.8, 2.0) 3.0 (2.9, 3.1)
4 1.2 (1.1, 1.3) 2.1 (2.0, 2.2) 3.2 (3.1, 3.4)
5 1.2 (1.2, 1.3) 2.2 (2.1, 2.3) 3.4 (3.3, 3.5)
6 1.3 (1.2, 1.4) 2.3 (2.2, 2.4) 3.6 (3.5, 3.7)
7 1.3 (1.2, 1.4) 2.5 (2.3, 2.6) 3.7 (3.5, 3.9)
8 1.3 (1.2, 1.4) 2.5 (2.3, 2.6) 3.7 (3.5, 3.9)
9 1.3 (1.2, 1.4) 2.5 (2.3, 2.6) 3.7 (3.5, 3.9)










Jonsson Funk et al. Page 13
Table 3
Cox proportional hazards regression analyses adjusting for age for time to sling revision/removal for mesh
erosion, urinary retention, and any indication.
Retention
Adj HR (95% CI)
Mesh Erosion
Adj HR (95% CI)
Any indication
Adj HR (95% CI)
Age
    18–29 1.91 (1.22, 2.99) 2.52 (1.58, 4.00) 2.02 (1.46, 2.80)
    30–39 1.19 (0.98, 1.45) 2.64 (2.19, 3.18) 1.69 (1.48, 1.93)
    40–49 0.87 (0.74, 1.02) 2.08 (1.76, 2.45) 1.28 (1.14, 1.43)
    50–59 0.91 (0.78, 1.07) 1.89 (1.60, 2.22) 1.22 (1.10, 1.37)
    60–69 0.91 (0.77, 1.08) 1.52 (1.28, 1.82) 1.10 (0.98, 1.24)
    70+ (ref) -- -- --
Procedure Location
    Inpatient     1.18 (1.06, 1.32) 1.04 (0.95, 1.15) 1.08 (1.00, 1.16)
    Outpatient (ref) -- -- --
Concomitant Surgerya
    Hysterectomy 0.98 (0.87, 1.10) 0.81 (0.73, 0.90) 0.84 (0.77, 0.91)
    Anterior Prolapse Surgery 1.22 (1.09, 1.36) 1.18 (1.08, 1.29) 1.18 (1.10, 1.27)
    Apical Prolapse Surgery 1.43 (1.25, 1.64) 1.24 (1.10, 1.41) 1.27 (1.16, 1.40)
    Posterior Prolapse Surgery 1.02 (0.85, 1.23) 1.06 (0.91, 1.24) 1.06 (0.94, 1.20)
a
Reference group includes those patients who did not have the specified procedure.
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